Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414414 | 0.91 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL5412284 | 0.89 | CRHR1 (0.46) | CRHR1CASR | |
| SCHEMBL5414711 | 0.88 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL5406569 | 0.88 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL5417755 | 0.87 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL5412064 | 0.87 | CRHR1 (0.61) | CRHR1 | |
| SCHEMBL5407484 | 0.84 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL5418981 | 0.84 | CRHR1 (0.61) | CRHR1 | |
| SCHEMBL6075245 | 0.84 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL5418485 | 0.82 | CRHR1 (0.63) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1500653-A1 | Substituted arylpyrazines | Neurogen Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | claimed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885CASR 737/4885 |
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885CASR 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.